Lexicon acquires rights to neuropathic pain candidate developed with BMS

Lexicon Pharmaceuticals has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lex…